BGI & MGI provide founding member Task Force Lab (TFL) immediate access to US FDA EUA COVID-19 testing equipment and reagents to ramp up capacity and reduce turnaround times San Jose, Calif. – September 22, 2020 – Today, BGI and MGI announced a clinical lab partnership program designed to accelerate population-level testing to help fight the on-going pandemic. The companies are leading global suppliers of COVID-19 (SARS-CoV-2) RT-PCR test kits and automated sample preparation systems, i...

In the last four decades, Professor Dr. Hans Lehrach has been one of the greatest pioneers and leading international personalities in functional and structural genome analysis research. In particular, his scientific activities and visions have contributed to accelerating the research approaches to these disciplines, especially in Germany. In 1978, as group leader at European Molecular Biology Laboratory in Heidelberg, Professor Dr. Lehrach contributed to develop positional cloning strate...

MGI has continued to advance lab automation with the launch of the first-of-its-kind high-throughput automated sample transfer processing system, MGISTP-7000. The product received the EU CE marking on August 14, 2020 and received Class I medical device qualification by the China’s NMPA on August 7, 2020, which streamlines the efficiency of front-end infectious sample handling across multiple regions. MGISTP-7000 integrates tube uncapping, tube recapping, barcode identification, automated...

Regarding the patent lawsuit initiated by Illumina against MGI in Hong Kong, the specific impact has yet to be determined. MGI believes that this patent litigation is an obvious attempt by Illumina to maintain a monopolistic market position and suppress the development of the industry. We intend to vigorously defend our intellectual property, and we have filed patent litigation against Illumina in U.S. District Court in California and Delaware. MGI has an extensive patent portfolio in the fiel...

China’s first “hospital version” of the Huo-Yan lab with MGI equipment has been established in the Third People’s Hospital of Shenzhen, a national clinical medical research center for infectious diseases. The hospital plans to build an automatic molecular detection platform for infectious diseases, promote rapid diagnosis and large-scale detection of pathogenic microorganisms, and enhance clinical inspection capability. This solution also helps the hospital complete full technical pre...

MGI is partnering with SIMED Peru to provide COVID-19 testing solutions for UNILABS and INS (Peru’s National Institute of Health) to meet demand for timely testing and reliable results at scale. Since the first case of COVID-19 was confirmed in March, the disease has spread in the country rapidly. On March 22, Peruvian President Martín Vizcarra set a daily testing capacity goal of 5,000. A molecular preventive laboratory was proposed, but the country’s Ministry of Health has now prior...